DR. MICHAEL JOHN MANYAK, MD
Urology at Blaine Dr, Bethesda, MD

6335321, Jan 1, 2002

Apr 21, 2000

09/556468

Steven R. Patierno - Falls Church VA
Michael J. Manyak - Chevy Chase MD

The George Washington University Medical Center - Washington DC

A61K 3800

514 21, 514 12

The invention relates to methods for identifying prostatic intraepithelial neoplasia, methods for determining metastatic potential of tumors, and to methods and compositions for inhibiting or preventing metastasis of cancers. In one aspect, the invention provides a method to determine metastatic potential of tumors, particularly prostatic tumors. In another aspect, the invention provides a method of identifying prostate cancer associated conditions, particularly prostatic intraepithelial neoplasia. In these regards, the invention relates to determining protein or mRNA of effectors of arachidonic acid release, particularly uteroglobin protein or mRNA, to identify intermediate conditions such as PIN or to gauge metastatic potential of prostatic tumors. The invention also relates to methods and compositions that prevent or inhibit metastasis of cancers. In this regard, the invention particularly relates to methods and compositions that inhibit arachidonic acid, those that inhibit phospholipase A.

6509316, Jan 21, 2003

Dec 9, 1997

08/987505

Steven R. Patierno - Falls Church VA
Michael J. Manyak - Chevy Chase MD

George Washington University - Washington DC

A61K 3514

514 12, 514 21, 530350, 530352, 530386, 530850, 530851, 530853

The present invention relates to pharmaceutical compositions, methods and kits that provide for the early diagnosis and treatment of lung cancer. More particularly, the present invention relates to pharmaceutical compositions containing uteroglobin for preventing or inhibiting metastasis of lung tumor cells and methods of using the same to prevent or inhibit metastasis of lung tumor cells. The present invention also relates to methods and kits for early diagnosis of metastatic lung cancer by assaying for uteroglobin and comparing the results against control cells. The present invention also relates to methods and kits for detection of metastatic lung cancer by assaying for the presence of an aberrant form of uteroglobin.

5935860, Aug 10, 1999

Jun 5, 1996

8/658796

Steven R. Patierno - Falls Church VA
Michael J. Manyak - Chevy Chase MD

The George Washington University - Washington DC

G01N 3348

436 64

The invention relates to methods for identifying prostatic intraepithelial neoplasia by determining the uteroglobin concentration in a tissue sample.

6358915, Mar 19, 2002

Dec 9, 1997

08/987502

Steven R. Patierno - Falls Church VA
Michael J. Manyak - Chevy Chase MD

George Washington University - Washington DC

A61K 3800

514 2, 514 45, 514 12, 514 15, 436501, 530350, 536 235

The invention relates to methods for determining degree of integrin-mediated maintenance of cell invasive capacity of tumors, and to methods and compositions for inhibiting or preventing metastasis of cancers. In one aspect, the invention provides a method to determine degree of integrin-mediated maintenance of cell invasive capacity of epithelial derived tumors, particularly prostatic, breast, and lung cancers. In these regards, the invention relates to determining protein or mRNA of effectors of integrin-mediated maintenance of cell invasive capacity, particularly uteroglobin protein or mRNA, or to gauge degree of integrin-mediated maintenance of cell invasive capacity of prostatic, breast, or lung tumors. The invention also relates to methods and compositions, such as uteroglobin, which specifically bind to integrin and are effectors of integrin-mediated maintenance of tumor cell invasive capacity and thus inhibit metastasis.

6395715, May 28, 2002

Apr 21, 2000

09/556467

Steven R. Patierno - Falls Church VA
Michael J. Manyak - Chevy Chase MD

The George Washington University Medical Center - Washington DC

A01N 4304

514 44, 424 932, 4353201

The present invention provides a novel method for inhibiting the growth of tumor cells of epithelial origin, comprising administration of a functional uteroglobin gene in a gene therapy regime, so as to inhibit growth of the tumor cells.

6316416, Nov 13, 2001

Feb 25, 2000

9/512385

Steven R. Patierno - Falls Church VA
Michael J. Manyak - Chevy Chase MD

A61K 3800, A61K 3816

514 21

The invention relates to method for identifying prostatic intraepithelial neoplasia, methods for determining metastatic potential of tumors, and to methods and compositions for inhibiting or preventing metastasis of cancers. In one aspect, the invention provides a method to determine metastatic potential of tumors, particularly prostatic tumors. In another aspect, the invention provides a method of identifying prostate cancer associated conditions, particularly prostatic intraepithelial neoplasia. In these regards, the invention relate to determining protein or mRNA of effectors of arachidonic acid release, particularly uteroglobin protein or mRNA, to identify intermediate conditions such as PIN or to gauge metastatic potential of prostatic tumors. The invention also relates to methods and compositions that prevent or inhibit metastasis of cancers. In this regard, the invention particularly relates to methods and compositions that inhibit arachidonic acid, those that inhibit phospholipase A. sub. 2.

5830640, Nov 3, 1998

Jun 7, 1995

8/486203

Steven R. Patierno - Falls Church VA
Michael Manyak - Chevy Chase MD

George Washington University - Washington DC

C12Q 100, G01N 3353, C07K 1600

435 4

The invention relates to methods for determining metastatic potential of tumors and to methods and compositions for inhibiting or preventing metastasis of cancers. In one aspect, the invention provides a method to determine metastatic potential of tumors, particularly prostatic tumors. In this regard the invention relates to determining protein or mRNA of effectors of arachadonic acid release to gauge metastatic potential, particularly uteroglobin protein or mRNA to determine metastatic potential of prostatic tumors. The invention also relates to methods and compositions that prevent or inhibit metastasis of cancers. In this regard, the invention particularly relates to methods and compositions that inhibit arachidonic acid, those that inhibit phospholipase A. sub. 2. More particularly in this regard, the invention relates to uteroglobin or muteins, peptide analogs or mimetics of uteroglobin and lipocortins or muteins, peptide analogs, or mimetics of lipocortins that inhibit metastasis. Especially it relates to methods and compositions in which uteroglobins, particularly human uteroglobins, inhibit or prevent metastasis of cancer, particularly prostatic cancer.

6054320, Apr 25, 2000

Nov 7, 1997

8/966196

Steven R. Patierno - Falls Church VA
Michael J. Manyak - Chevy Chase MD

George Washington University - Washington DC

G03G 1504

436 64

The invention relates to methods for identifying prostatic intraepithelial neoplasia, methods for determining metastatic potential of tumors, and to methods and compositions for inhibiting or preventing metastasis of cancers. In one aspect, the invention provides a method to determine metastatic potential of tumors, particularly prostatic tumors. In another aspect, the invention provides a method of identifying prostate cancer associated conditions, particularly prostatic intraepithelial neoplasia. In these regards, the invention relates to determining protein or mRNA of effectors of arachidonic acid release, particularly uteroglobin protein or mRNA, to identify intermediate conditions such as PIN or to gauge metastatic potential of prostatic tumors. The invention also relates to methods and compositions that prevent or inhibit metastasis of cancers. In this regard, the invention particularly relates to methods and compositions that inhibit arachidonic acid, those that inhibit phospholipase A. sub. 2.

5696092, Dec 9, 1997

Mar 7, 1995

8/400084

Steven R. Patierno - Falls Church VA
Michael Manyak - Chevy Chase MD

George Washington University - Washington DC

A61K 3817

514 21

The present invention relates to methods and compositions that prevent or inhibit metastases of cancers of epithelial cell origin, especially human prostate cancers. A particular aspect of the invention relates to methods and compositions that inhibit arachidonic acid release in cells of these cancers and inhibit or prevent metastasis. In one aspect in this regard, the invention particularly relates to methods and compositions that inhibit phospholipase A. sub. 2 that mediates arachidonic acid release in the cancer cells. In a further aspect, the invention relates to methods and compositions wherein uteroglobin, uteroglobin muteins, peptide analogs of uteroglobins, lipocortins, lipocortin muteins and peptide analogs of lipocortins inhibit arachidonic acid release by cancer cells. In this regard, the invention relates especially to uteroglobins, particularly human uteroglobins.